Document Detail


Antagonizing IL-6 in Ankylosing Spondylitis: A Short Review.
MedLine Citation:
PMID:  22452603     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Ankylosing spondylitis (AS) is a chronic inflammatory disorder with predilection for the axial skeleton, leading to progressive restricted mobility and deformity of the spine. The fundamental mechanism involves autoimmunity orchestrated by T cells. Similar to other rheumatic diseases, the complex interplay of cytokines such as tumour necrosis factor alpha, interleukin-6 (IL 6) and interleukin-10 (IL 10) have been implicated in the pathogenesis of the disease. Despite extensive research over the past decades, the treatment options for AS, are limited. Non steroidal anti-inflammatory drugs are the first line of therapy, whereas anti TNF drugs are administered for refractory cases which fail to respond to the treatment. There have been conflicting views on the correlation of IL 6 with disease activity in AS. As such, the debate on the role of anti IL6 in AS is still ongoing. Anti IL 6 such as tocilizumab and siltuximab have proven efficacy based on the large randomized controlled trials. The Food and Drug Administration (FDA) has approved these drugs for treating rheumatoid arthritis and systemic juvenile idiopathic arthritis. Researchers have adventurously experimented anti IL 6 therapy in AS but the conclusions made were not consolidated into international guidelines or consensus statement for clinical practice. In the present review, we explore the role of anti IL6 in the treatment of AS based on the cumulative evidence over recent years.
Authors:
Sakthiswary Rajalingham; Srijit Das
Related Documents :
22525083 - Designing a novel in vitro drug-release-testing method for liposomes prepared by ph-gra...
22694953 - Ex vivo drug sensitivity profiles of plasmodium falciparum field isolates from cambodia...
17021453 - Patients on party drugs undergoing anesthesia.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-28
Journal Detail:
Title:  Inflammation & allergy drug targets     Volume:  -     ISSN:  2212-4055     ISO Abbreviation:  Inflamm Allergy Drug Targets     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101266886     Medline TA:  Inflamm Allergy Drug Targets     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abd Aziz, 53000, Kuala Lumpur, Malaysia. drsrijit@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy of montelukast as added therapy in patients with chronic idiopathic urticaria.
Next Document:  Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a ...